Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
106 hedge funds and large institutions have $39.9M invested in Acorda Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 37 reducing their positions, and 25 closing their positions.
11% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 37
12% less funds holding
Funds holding: 121 → 106 (-15)
52% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 25
62% less capital invested
Capital invested by funds: $106M → $39.9M (-$65.8M)
98% less call options, than puts
Call options by funds: $79K | Put options by funds: $3.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.08M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$921K |
| 3 |
JP Morgan Chase
New York
|
+$536K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$411K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.09M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.94M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$857K |
ACOR Hedge Fund Activity: Q1 2020 in Review
106 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2020, worth a combined $39.9M — down 62% from $106M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACOR and 12 opened new positions — a net loss of 13 holders — while 37 trimmed existing stakes and 33 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.08M. The largest seller was Point72 Asset Management, cutting an estimated $5.09M.
- 106 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2020, down from 121 in Q4 2019.
- Funds reported $39.9M of Acorda Therapeutics stock for Q1 2020, down 62% quarter-over-quarter.
- 12 funds opened new Acorda Therapeutics positions in Q1 2020 and 25 closed out, a net change of -13 holders.
- The largest Acorda Therapeutics buyer in Q1 2020 was Susquehanna International Group, an estimated $1.08M added.
- The largest Acorda Therapeutics seller in Q1 2020 was Point72 Asset Management, an estimated $5.09M sold.
Based on aggregated 13F filings for Q1 2020.